



an Open Access Journal by MDPI

Thyroid Cancer: From Biology to Therapeutic Opportunities

Guest Editors:

Dr. Cristina Alina Silaghi

Department of Endocrinology,
"Iuliu Hațieganu" University of
Medicine and Pharmacy Cluj-
Napoca, 8 Victor Babes Street,
400012 Cluj-Napoca, Romania

**Prof. Dr. Carmen Emanuela
Georgescu**

Department of Endocrinology,
"Iuliu Hațieganu" University of
Medicine and Pharmacy Cluj-
Napoca, 8 Victor Babes Street,
400012 Cluj-Napoca, Romania

Dr. Horațiu Silaghi

Department of Surgery V, "Iuliu
Hațieganu" University of
Medicine and Pharmacy Cluj-
Napoca, 8 Victor Babes Street,
400012 Cluj-Napoca, Romania

Deadline for manuscript
submissions:

closed (30 September 2023)

Message from the Guest Editors

Thyroid cancer (TC) is the most common endocrine neoplasia. In recent years, TC studies have dramatically improved the understanding of the molecular mechanisms leading to the initiation and progression of TC.

The promising results of the immune checkpoint inhibitors used in patients with TC highlight the critical role of the immune system in TC advancement. Furthermore, the recent achievements in molecular biology represent the starting point for new genetic and epigenetic research aiming to delve into thyroid carcinogenesis and, consequently, help to achieve a better outcome in advanced TC cases.

This Special Issue aims to present the latest research in the molecular landscape, which may contribute to decoding pathogenesis, refining diagnosis, prognosis, and therapy of TC. You are welcome to submit for publication systematic or narrative reviews, original research, animal or cell culture models that provide new insights into the molecular mechanisms and may have an impact on TC management.



mdpi.com/si/138756

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)